The aim of the present study was to investigate the clinicopathologic characteristics of TP53 mutation in ALK‐rearranged NSCLC and its association with the effect of crizotinib in ALK‐rearranged NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.